BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 12957251)

  • 1. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer.
    Antonadou D; Throuvalas N; Petridis A; Bolanos N; Sagriotis A; Synodinou M
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):402-8. PubMed ID: 12957251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
    Antonadou D; Petridis A; Synodinou M; Throuvalas N; Bolanos N; Veslemes M; Sagriotis A
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):2-9. PubMed ID: 14727235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.
    Antonadou D
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):50-8. PubMed ID: 11917285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
    Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
    J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
    Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
    J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of treatment breaks and radiation-induced esophagitis and pneumonitis using amifostine in unresectable non-small cell lung cancer patients receiving definitive concurrent chemotherapy and radiation therapy: a prospective community-based clinical trial.
    Wynn RB; Mehta V
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S99-104. PubMed ID: 16015543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer.
    Antonadou D; Coliarakis N; Synodinou M; Athanassiou H; Kouveli A; Verigos C; Georgakopoulos G; Panoussaki K; Karageorgis P; Throuvalas N;
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):915-22. PubMed ID: 11704311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
    Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.
    Komaki R; Lee JS; Kaplan B; Allen P; Kelly JF; Liao Z; Stevens CW; Fossella FV; Zinner R; Papadimitrakopoulou V; Khuri F; Glisson B; Pisters K; Kurie J; Herbst R; Milas L; Ro J; Thames HD; Hong WK; Cox JD
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):46-9. PubMed ID: 11917284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
    Mehta V
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy.
    Komaki R; Chang JY; Wu X; Allen PK; Milas L; Liao Z; Fossella FV; Travis E; Spitz MR
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S92-8. PubMed ID: 16015542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
    Tannehill SP; Mehta MP; Larson M; Storer B; Pellet J; Kinsella TJ; Schiller JH
    J Clin Oncol; 1997 Aug; 15(8):2850-7. PubMed ID: 9256128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings.
    Senzer N
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):38-41. PubMed ID: 12577242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
    Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of combined radiation, paclitaxel and carboplatin for locally advanced non-small cell lung carcinoma.
    Nguyen NP; Leonardo JM; Karlsson U; Vos P; Bullock L; Thomas P; Lepera P; Ludin A; Chu C; Salehpour M; Jendrasiak G; Sallah S
    Anticancer Res; 2002; 22(6B):3429-35. PubMed ID: 12552935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01.
    Werner-Wasik M; Langer C; Movsas B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):47-51. PubMed ID: 15726523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
    Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer.
    Büntzel J; Glatzel M; Kuttner K; Weinaug R; Fröhlich D
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):4-13. PubMed ID: 11917277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.